Biotech in Belgium: news and updates

News and Trends 28 May 2015

Biotechs outperformed in the top 40 European Tech Companies

EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs (Small and Medium-size companies), announced the launch of Tech 40, a label recognizing innovative European SMEs. Tech 40 puts young tech companies listed on Euronext markets – in Amsterdam, Brussels, Lisbon or Paris – under the spotlight. Companies awarded with the Tech 40 are operating in […]

May 28, 2015 - 2 minutesmins - By Nicolas Sainte-Foie

News and Trends 22 May 2015

Genzyme joins the never-ending list of Ablynx’ partners

Genzyme is joining Ablynx’ partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Sanofi subsidiary now wants to try out the Nanobody technology of Ablynx against a target at the origin of multiple sclerosis. Genzyme wants to investigate nanobodies against a target that specifically aligns with Genzyme’s early-stage multiple […]

May 22, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 20 May 2015

[UPDATE] Galapagos with €277.3M, made the Biggest European Biotech IPO ever on NASDAQ

[UPDATE 20/05/2015]: Galapagos announced the closing of its NASDAQ IPO, where the company raised a total of €277.3M. Galapagos has once again made the front page thanks to its unbeaten IPO. The company just raised €240M on Nasdaq, becoming the biggest European biotech IPO ever on the US stock market. The Belgium company just ranked […]

May 20, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 May 2015

Ablynx gets tangled up in partnerships with Big Pharma companies

The Belgium-based company is leading more than 20 pre-clinical and clinical programmes with several partners to put the Nanobody technology on the market. Companies such as AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis are part of Ablynx’s dream team. Ablynx is a biotech company developing Nanobodies. Nanobody technology was originally developed […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 11 May 2015

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest […]

May 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 29 Apr 2015

Biocartis shakes Euronext with an IPO that raised €100M

Last Monday, Belgian Biocartis launched an IPO that quickly raised €100M; the offering was closed a week ahead of schedule. The unquestionable interest of the investors, both in Belgium and internationally, shows the company’s potential and the appeal of its technology. The company, which raised €64.5M in September in a private financial round, intends to […]

April 29, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 11 Apr 2015

Cardio3 Biosciences Embedded BioLife Solutions for a Heart Regenerative Therapy

Cardio3 BioSciences is again on the front page of biotech news. After announcing the launching of an IPO on Nasdaq and getting an US patent, the company has now embedded the BioLife Solutions‘ clinical grade CryoStor cryopreservation freeze media, in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial […]

April 11, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 8 Apr 2015

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Just a week after announcing its intention to launch an IPO in the United States, Cardio3 Biosciences continues increasing its presence in the States. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a significant patent application broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Apr 2015

Cardio3 will launch an IPO in the United States

Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced its intention to conduct a registered public offering in the United States. The timing, number of shares and price of the proposed offering have not yet been determined. A draft registration statement relating to […]

April 1, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 13 Mar 2015

Orgenesis acquires MaSTherCell

Orgenesis acquired MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics based in Gosselies, Belgium, as part of the American company’s plan to increase its global presence and capabilities. The American and the Belgian companies have already been working jointly since last year to scale manufacturing of Orgenesis’ insulin-producing liver cells to fight diabetes. […]

March 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Dec 2014

After Merck’s Big Deal, Pfizer Collaborates with iTeos Therapeutics for Cancer Treatments

iTeos Therapeutics SA enters in a strategic collaboration with Pfizer Inc where iTeos will license to Pfizer rights to iTeos’ pre-clinical compounds targeting the enzymes expressed in many cancers. Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. It completes a previous deal with Merck a few weeks ago. Additionally, […]

December 11, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 25 Nov 2014

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, raised 25,33 million euros. The major innovation of Promethera HepaStem is based on Heterologous Human Adult Liver Progenitor Cells (HHALPC). It is a potential to treat a wide variety of congenital […]

November 25, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us